

# Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2019

<https://marketpublishers.com/r/NB58190C0D7EN.html>

Date: April 2019

Pages: 296

Price: US\$ 2,000.00 (Single User License)

ID: NB58190C0D7EN

## Abstracts

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2019

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2019, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape.

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 21, 13, 1, 31 and 9 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Non Alcoholic Fatty Liver Disease (NAFLD) - Overview

Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Development

Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment

Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics  
Development

Non Alcoholic Fatty Liver Disease (NAFLD) - Drug Profiles

Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects

Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products

Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Akcea Therapeutics Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Ardelyx Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by AstraZeneca Plc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Betagenon AB, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by BioElectron Technology Corp, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Bird Rock Bio Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Boehringer Ingelheim GmbH, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Cadila Healthcare Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Can-Fite BioPharma Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Carmot Therapeutics Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Cerenis Therapeutics Holding SA, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Corcept Therapeutics Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dr. Falk Pharma GmbH, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by DURECT Corp, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Eli Lilly and Co, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Enanta Pharmaceuticals Inc,

H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Eternygen GmbH, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Evgen Pharma Plc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Galmed Pharmaceuticals Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gemphire Therapeutics Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by GemVax & KAEL Co Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gilead Sciences Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by HemoShear Therapeutics, LLC, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Huons Global Co Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Immuron Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Inventiva, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Ionis Pharmaceuticals Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kinomedica Pty Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kowa Co Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Mallinckrodt Plc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Metacrine Inc, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Mina Therapeutics Ltd, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Novartis AG, H1 2019

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by NuSirt Biopharma Inc, H1 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

### COMPANIES MENTIONED

Akcea Therapeutics Inc

Ardelyx Inc

AstraZeneca Plc

Betagenon AB

BioElectron Technology Corp

Bird Rock Bio Inc

Boehringer Ingelheim GmbH

Cadila Healthcare Ltd

Can-Fite BioPharma Ltd

Carmot Therapeutics Inc

Cerenis Therapeutics Holding SA

Corcept Therapeutics Inc

Dr. Falk Pharma GmbH

DURECT Corp

Eli Lilly and Co

Enanta Pharmaceuticals Inc

Eternygen GmbH

Evgen Pharma Plc

F. Hoffmann-La Roche Ltd

Galmed Pharmaceuticals Ltd

Gemphire Therapeutics Inc



GemVax & KAEL Co Ltd  
Gilead Sciences Inc  
Guangdong Zhongsheng Pharmaceutical Co Ltd  
Hanmi Pharmaceuticals Co Ltd  
HemoShear Therapeutics, LLC  
Huons Global Co Ltd  
Immuron Ltd  
Inventiva  
Ionis Pharmaceuticals Inc  
Kinomedica Pty Ltd  
Kowa Co Ltd  
Kyorin Pharmaceutical Co Ltd  
Mallinckrodt Plc  
Metacrine Inc  
Mina Therapeutics Ltd  
Novartis AG  
NuSirt Biopharma Inc  
Pfizer Inc  
Phenex Pharmaceuticals AG  
Renova Therapeutics Inc  
Ritter Pharmaceuticals Inc  
Sancilio & Company Inc  
Shenzhen HighTide Biopharmaceutical Ltd  
T3D Therapeutics Inc  
TaiwanJ Pharmaceuticals Co Ltd  
TCM Biotech International Corp  
Theratechnologies Inc  
Tiziana Life Sciences Plc  
Viking Therapeutics Inc

## I would like to order

Product name: Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2019

Product link: <https://marketpublishers.com/r/NB58190C0D7EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NB58190C0D7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970